ZBH - Zimmer Biomet Holdings, Inc.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

Is Now An Opportune Moment To Examine Zimmer Biomet Holdings, Inc. (NYSE:ZBH)?

Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) received a lot of attention from a substantial price movement on the NYSE...

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.

Here's Why You Should Invest in IDEXX (IDXX) Right Now

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Zimmer (ZBH) Down 8.8% Since Last Earnings Report: Can It Rebound?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• 
  Air Products and Chemicals (APD) Up 0.5% Since Last Earnings Report: Can It Continue?

  Zacks
• 
  Why Is Steris (STE) Down 0.9% Since Last Earnings Report?

  Zacks

Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)

Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why You Should Retain Integra (IART) Stock Now

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

• 
  OTIS Launches the Digitally Connected Gen3 Core Elevator

  Zacks
• 
  D.R. Horton (DHI) Reaches 52-Week High: What's Driving It?

  Zacks

ZBH vs. RMD: Which Stock Should Value Investors Buy Now?

ZBH vs. RMD: Which Stock Is the Better Value Option?

• 
  AGCO or LNN: Which Is the Better Value Stock Right Now?

  Zacks
• 
  CLVT vs. INFA: Which Stock Is the Better Value Option?

  Zacks

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

• 
  Heres Why Hold Strategy is Apt for Hanover Insurance (THG)

  Zacks
• 
  Factors That Make Manitowoc (MTW) a Lucrative Bet Now

  Zacks

Here's Why Investors Should Hold Encompass Health (EHC) Now

Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.

• 
  Reasons to Add Pampa Energia (PAM) to Your Portfolio Right Now

  Zacks
• 
  Greif (GEF) Earnings Surpass Estimates in Q2, Sales Miss

  Zacks

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

• 
  General Electric (GE) Up 27% YTD: Will the Momentum Continue?

  Zacks
• 
  Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow

  Zacks

Boston Scientific (BSX) Gains From Acquisitions, New Launches

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

• 
  Heres Why Hold Strategy is Apt for Hanover Insurance (THG)

  Zacks
• 
  General Electric (GE) Up 27% YTD: Will the Momentum Continue?

  Zacks

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

• 
  Looking for Industrial Products Stocks? The Zacks Rank Can Help You Find Winners

  Zacks
• 
  Richardson Electronics (RELL) Outpaces Stock Market Gains: What You Should Know

  Zacks

Here's Why You Should Retain Insulet (PODD) Stock for Now

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

The Returns At Zimmer Biomet Holdings (NYSE:ZBH) Aren't Growing

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

• 
  General Electric (GE) Up 27% YTD: Will the Momentum Continue?

  Zacks
• 
  D.R. Horton (DHI) Reaches 52-Week High: What's Driving It?

  Zacks

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

• 
  General Electric (GE) Up 27% YTD: Will the Momentum Continue?

  Zacks
• 
  Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

  Zacks

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.